PureTech Health/$PRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PureTech Health
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Ticker
$PRTC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
56
ISIN
US7462371060
Website
PureTech Health Metrics
BasicAdvanced
$423M
85.43
$0.21
0.90
-
Price and volume
Market cap
$423M
Beta
0.9
52-week high
$26.79
52-week low
$13.30
Average daily volume
4.5K
Financial strength
Current ratio
9.333
Quick ratio
9.186
Long term debt to equity
37.127
Total debt to equity
40.59
Interest coverage (TTM)
-13.54%
Profitability
EBITDA (TTM)
-134.062
Gross margin (TTM)
-1,333.89%
Net profit margin (TTM)
1,108.33%
Operating margin (TTM)
-2,814.19%
Effective tax rate (TTM)
-16.86%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-13.10%
Return on equity (TTM)
6.41%
Valuation
Price to earnings (TTM)
85.429
Price to revenue (TTM)
945.554
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-33.97
Free cash flow yield (TTM)
-2.94%
Free cash flow per share (TTM)
-52.81%
Growth
Revenue change (TTM)
44.98%
Earnings per share change (TTM)
-187.50%
3-year revenue growth (CAGR)
-34.76%
10-year revenue growth (CAGR)
8.07%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
-8.49%
What the Analysts think about PureTech Health
Analyst ratings (Buy, Hold, Sell) for PureTech Health stock.
Bulls say / Bears say
PureTech Health's wholly owned program, deupirfenidone, achieved positive results in a Phase 2b trial for idiopathic pulmonary fibrosis, indicating strong potential for future approvals and market adoption. (marketbeat.com)
The FDA approval of KarXT, a treatment for schizophrenia invented at PureTech, marks a significant validation of the company's R&D capabilities and could lead to increased revenue streams. (investing.com)
Analysts at Leerink Partners initiated coverage on PureTech Health with an 'outperform' rating and a $45.00 price target, suggesting a potential upside of over 100% from the current stock price. (marketbeat.com)
PureTech Health reported a net loss of $66.6 million in 2023, raising concerns about the company's profitability and financial sustainability. (wikipedia.org)
The company's stock price has experienced significant volatility, with a 52-week low of $18.19, which may indicate investor uncertainty and potential downside risk. (investing.com)
Despite positive trial results, the competitive landscape in the biotechnology sector remains intense, potentially limiting PureTech's market share and revenue growth. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
PureTech Health Financial Performance
Revenues and expenses
PureTech Health Earnings Performance
Company profitability
PureTech Health News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PureTech Health stock?
PureTech Health (PRTC) has a market cap of $423M as of June 27, 2025.
What is the P/E ratio for PureTech Health stock?
The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 85.43 as of June 27, 2025.
Does PureTech Health stock pay dividends?
No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next PureTech Health dividend payment date?
PureTech Health (PRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for PureTech Health?
PureTech Health (PRTC) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.